Business Context and Reporting Period
This Form 8-K filing by Spero Therapeutics, Inc. (SPRO) reports a material corporate event dated September 4, 2019. The company is a clinical-stage biopharmaceutical firm incorporated in Delaware and listed on the Nasdaq Global Select Market.
Financial Metrics
The filing text does not provide specific financial data, including revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on executive personnel changes.
Material Changes
- Executive Departure: Joel Sendek resigned as Chief Financial Officer (CFO) effective September 4, 2019.
- Reason for Departure: Mr. Sendek is leaving to pursue a new opportunity closer to his home in the New York metropolitan area. He explicitly stated the resignation was not due to any disagreement with the Board or company operations.
- Transition Plan: Mr. Sendek will remain with the company through the filing of the Form 10-Q for the quarter ending September 30, 2019, to ensure a smooth transition.
- Succession: The company has commenced a search for a new Chief Financial Officer.
Management Commentary and Outlook
CEO Ankit Mahadevia, M.D., acknowledged Mr. Sendek's significant contributions over the last two and a half years in building Spero into a public, clinical-stage company with multiple medicines in trials. Mr. Sendek expressed confidence in the senior leadership team and the finance organization to continue driving success for shareholders and patients.
Key Facts for Investor Verification
- Confirm the timeline for the appointment of a new CFO.
- Review the upcoming Form 10-Q for the quarter ended September 30, 2019, for financial performance data not included in this 8-K.
- Monitor for any further announcements regarding the search for a permanent CFO replacement.